Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Veerle Van Eygen"'
Autor:
Alessandro Cozzi-Lepri, Lars Peters, Annegret Pelchen-Matthews, Bastian Neesgaard, Stephane De Wit, Isik Somuncu Johansen, Simon Edwards, Christoph Stephan, Georgios Adamis, Therese Staub, Alexandra Zagalo, Pere Domingo, Daniel Elbirt, Katharina Kusejko, Johanna Brännström, Dzmitry Paduta, Tatyana Trofimova, Janos Szlavik, Kai Zilmer, Marcello Losso, Veerle Van Eygen, Helen Pai, Jens Lundgren, Amanda Mocroft, for the EuroSIDA Study Group
Publikováno v:
AIDS Research and Therapy, Vol 19, Iss 1, Pp 1-12 (2022)
Abstract Introduction Data on safety and effectiveness of RPV from the real-world setting as well as comparisons with other NNRTIs such as efavirenz (EFV) remain scarce. Methods Participants of EuroSIDA were included if they had started a RPV- or an
Externí odkaz:
https://doaj.org/article/52e7fe1dd5e244669b712b449eee7437
Autor:
Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil
Publikováno v:
Health Science Reports, Vol 3, Iss 2, Pp n/a-n/a (2020)
Abstract Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult‐to‐cure/cirrhoti
Externí odkaz:
https://doaj.org/article/61e6a0119abd4699b62cba409899ce21
Autor:
Ina Vandenbroucke, Herwig Van Marck, Peter Verhasselt, Kim Thys, Wendy Mostmans, Stéphanie Dumont, Veerle Van Eygen, Katrien Coen, Marianne Tuefferd, Jeroen Aerssens
Publikováno v:
BioTechniques, Vol 51, Iss 3, Pp 67-77 (2011)
Ultra-deep sequencing (UDS) of amplicons is a major application for next-generation sequencing tech nologies, even more so for the 454 Genome Sequencer FLX. Especially for this application, errors that might be introduced during any of the sample pro
Externí odkaz:
https://doaj.org/article/29b23da48c624d15b762778e9046affd
Autor:
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Anders Thalme, Pierre-Marie Girard, Alexander Wong, Norma Porteiro, Susan Swindells, Jacques Reynes, Sebastian Noe, Conn Harrington, Carlos Martín Español, Carolina Acuipil, Asma Aksar, Yuanyuan Wang, Susan L Ford, Herta Crauwels, Veerle van Eygen, Rodica Van Solingen-Ristea, Christine L Latham, Shanker Thiagarajah, Ronald D’Amico, Kimberly Y Smith, Kati Vandermeulen, William R Spreen
Publikováno v:
Clinical Infectious Diseases. 76:1646-1654
Background Cabotegravir (CAB) + rilpivirine (RPV) dosed intramuscularly monthly or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 virologic suppression. Here, we report the antiretroviral therapy as long acting su
Autor:
Ronald D'Amico, Santiago Cenoz Gomis, Riya Moodley, Rodica Van Solingen‐Ristea, Bryan Baugh, Erika Van Landuyt, Veerle Van Eygen, Sherene Min, Amy Cutrell, Caroline Foster, Daniella Chilton, Sabine D. Allard, Annemiek Ruiter
Publikováno v:
HIV Medicine. 24:202-211
OBJECTIVES: Physicians could request compassionate use of oral and long-acting (LA) cabotegravir + rilpivirine for people living with HIV-1 under a single-patient request programme supported by ViiV Healthcare and Janssen. Outcomes are reported. METH
Autor:
Veerle Van Eygen, David A. Margolis, Marty St. Clair, Jerry Jeffrey, Daniel R. Kuritzkes, Michael Aboud, Jan van Lunzen, Yongwei Wang, William Spreen, Christine L. Talarico, Mark Baker, Kati Vandermeulen, Amy Cutrell, Carlo Federico Perno, Jonathan M. Schapiro, David Dorey, Susan L. Ford, Herta Crauwels, C. Thomas White, Joseph W. Polli, Romina Quercia, Simon Vanveggel, Sterling Wu, Parul Patel
Publikováno v:
AIDS (London, England)
Current antiretroviral therapy (ART) consists of a combination of two or more oral agents from at least two drug classes, such as an integrase strand transfer inhibitor (INSTI) as well as one or two nucleoside reverse transcriptase inhibitors (NRTIs)
Autor:
Miguel García Deltoro, Veerle Van Eygen, Paul D Benn, Kimberly Y. Smith, Hans Jaeger, Parul Patel, Fritz Bredeek, Rodica Van Solingen-Ristea, Christine L. Talarico, William Spreen, Marie-Aude Khuong-Josses, Simon Vanveggel, Susan L. Ford, Gary Richmond, Edgar T. Overton, Giuliano Rizzardini, Krischan J Hudson, Amy Cutrell, Susan Swindells, Vasiliki Chounta, Jaime Andrade-Villanueva, Catherine Orrell, Herta Crauwels, David A. Margolis, Mark S. Shaefer, Firaya Nagimova, Yuanyuan Wang, Alexander Wong
Publikováno v:
The Lancet. 396:1994-2005
Phase 3 clinical studies showed non-inferiority of long-acting intramuscular cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important phase 2 results of every 8 weeks dosing, and supportive modelling, underpin furthe
Autor:
Luminita Ene, Natalia Zakharova, Rodica Van Solingen-Ristea, Veerle Van Eygen, Pedro Cahn, Eric Van Wijngaerden, Simon Vanveggel, Gerd Fätkenheuer, Johan Lombaard, Jean-Michel Molina
Publikováno v:
Antiviral therapy. 26(6-8)
Background To evaluate the long-term safety and efficacy of rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), in combination with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in human immunodeficiency viru
Autor:
Jerry L. Jeffrey, Marty St. Clair, Ping Wang, Chunfu Wang, Zhufang Li, Jagadish Beloor, Christine Talarico, Robert Fridell, Mark Krystal, C. Thomas White, Sandy Griffith, Ronald D’Amico, Kimberly Smith, Veerle Van Eygen, Johan Vingerhoets, Kati Vandermeulen, William Spreen, Jan van Lunzen
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir + rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression. Three participants who received long-acting therapy had confirmed
Autor:
Johan Lombaard, Francis Ssali, Puthanakit Thanyawee, Jan Fourie, Simon Vanveggel, Cornelia Linthicum, Veerle Van Eygen, Rodica Van Solingen-Ristea
Publikováno v:
Antimicrobial agents and chemotherapy. 66(2)
This phase 2 study investigated long-term safety and efficacy of rilpivirine (RPV [Edurant]) plus two investigator-selected nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in HIV-1-infected antiviral therapy-naive adolescents. Participants (